Trastuzumab, a monoclonal antibody against HER2, is the only approved targeted agent that has been shown to confer overall survival benefit in the first‐line treatment of HER2‐positive advanced GC (AGC) patients.3 Here, ERBB2 is linked to gastric cancer.